Compare Aegon Ltd. (AEG) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aegon Ltd. vs Merck & Co., Inc. — how do they compare? Aegon Ltd. trades at $8.73 (market cap $12.98B), while Merck & Co., Inc. trades at $126.01 (market cap $318.26B). The key difference: Merck & Co., Inc. is far larger — about 24.5× Aegon Ltd.'s market cap, and Aegon Ltd. pays the higher dividend (5.3%). Which is the better fit depends on your goals.
| AEG | MRK | |
|---|---|---|
Market Cap | $12.98B | $318.26B |
Sector | Financials | Health |
52-Week High | $8.79 | $129.52 |
52-Week Low | $6.79 | $77.60 |
Enterprise Value | $14.11B | $361.68B |
Dividend Yield | 5.3% | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEG trades at $8.75, up 1.04% on the day, with a P/E of 12.86 and P/S of 0.55 indicating potential undervaluation. Recent earnings show mixed results, beating estimates in Q2 and Q3 2025 but missing in Q4. The company is undergoing strategic simplification, including moving its legal seat to Delaware and focusing on U.S. operations, supported by a dividend of $0.25 payable in July 2026. Technical indicators are bullish on moving averages but neutral on oscillators.
Outlook is cautiously optimistic with a 27.78% analyst buy rating, driven by restructuring benefits and U.S. market focus. Risks include execution challenges in the transition, volatile cash flows, and competitive pressures. The stock presents a value opportunity if the strategic pivot succeeds, but investors should monitor earnings consistency and debt management.
Merck (MRK) trades at $126.00, down 0.62% today, with a bullish technical outlook supported by moving averages and strong institutional buying. The company reported solid earnings beats in recent quarters, with Q1 2026 loss narrower than expected. Revenue reached $65.01B in 2025, with net income margin improving to 28.07%. Recent acquisition of Terns Pharmaceuticals for approximately $6.7 billion aims to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook remains positive with a consensus price target of $139.33, implying 11% upside, supported by 67.6% analyst buy ratings. Risks include rising debt-to-asset ratio to 36.06% in 2025 and projected net cash flow decline to -$3.3B in 2026. Competitive pressures in pharma and macroeconomic uncertainties could challenge growth, but strong profitability and dividend yield offer defensive appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
